Why the study?
Does high-dose intravenous gammaglobulin improve the clinical course in patients with severe Guillain-Barré syndrome?
Does high-dose intravenous gammaglobulin improve the clinical course in patients with severe Guillain-Barré syndrome?
Answers are grounded in this paper and cite their sources.
High-dose intravenous gammaglobulin may provide clinical benefit in severe Guillain-Barré syndrome, warranting further investigation in randomized trials.
Intravenous gammaglobulin (IVGG) can improve the clinical course of several immune-mediated diseases. We report the first results of such treatment in eight patients with severe Guillain-Barré syndrome (GBS). We observed that IVGG was beneficial in at least some of the patients with severe GBS. These results should be confirmed in a randomized trial.
No takes yet. Share an insight, caveat, or question.
Kleyweg et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: